Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma Clear all
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
673
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions
PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced May 21, 2026, 11:13 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Carcinoma, Neuroendocrine
Interventions
Selinexor
Drug
Lead sponsor
Gabrail Cancer Center Research
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced May 21, 2026, 11:13 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic or Locally Advanced Neuroendocrine Prostate Cancer, Metastatic or Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic or Locally Advanced Merkel Cell Carcinoma, Locally Advanced or Metastatic Large Cell Neuroendocrine Carcinoma of the Lung, Metastatic or Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Poorly Differentiated and/or High Grade Neuroendocrine Neoplasms With Evidence of DLL3 Expression
Interventions
BL-M14D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 21, 2026, 11:13 PM EDT